Tag Archives: inhibitor

Merck and Hengrui Unite for Pioneering Cancer Therapies Worldwide

(IN BRIEF) Merck, a prominent science and technology company, has entered into a strategic partnership with Jiangsu Hengrui Pharmaceuticals. This collaboration includes an exclusive global license (excluding China) to develop and commercialize Hengrui’s advanced PARP1 inhibitor, HRS-1167. Additionally, there is … Read the full press release

Novartis Reports Positive Phase III Outcomes for Novel Chronic Spontaneous Urticaria Drug

TOP-LINE DATA FROM REMIX-1 AND REMIX-2 STUDIES DEMONSTRATE SIGNIFICANT SYMPTOM IMPROVEMENT (IN BRIEF) Novartis has unveiled promising results from Phase III trials for remibrutinib, a potent Bruton’s tyrosine kinase (BTK) inhibitor, targeting chronic spontaneous urticaria (CSU). The REMIX-1 and REMIX-2 … Read the full press release

New Advancement in Prostate Cancer Treatment: Darolutamide Set to be Approved in EU

Not intended for U.S. and UK Media (IN BRIEF) The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended darolutamide, an oral androgen receptor inhibitor, for marketing authorization in the European Union as a treatment for patients … Read the full press release

ESMO Virtual Congress 2020: Libtayo positive pivotal data offer hope for the treatment of advanced basal cell carcinoma, a difficult-to-treat cancer

Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial 31% objective response rate seen in trial patients, and an estimated 85% of responses … Read the full press release

Novartis announces EC approval for Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for adjuvant treatment of BRAF V600 mutation-positive melanoma

Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients   More than 50% of stage III melanoma patients are likely to recur to stage IV during their lifetime … Read the full press release

Novartis: the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 has met the primary endpoint

SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase inhibitor with or without a CDK4/6 inhibitor[1] Approximately 40% of HR+ advanced breast cancer … Read the full press release

AstraZeneca: Japan approval for Lynparza (olaparib) tablets for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer

Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status CAMBRIDGE, 22-Jan-2018 — /EuropaWire/ — AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, … Read the full press release

Biotie Therapies started clinical study evaluating nepicastat in cocaine dependence

Turku, 29-5-2013 — /europawire.eu/ — Biotie Therapies today announced the start of a Phase 2 clinical study evaluating nepicastat (SYN117) in cocaine dependence. The National Institute on Drug Abuse (NIDA) at the US National Institutes of Health is funding the conduct … Read the full press release